IndraLab
Statements
Vorinostat inhibits mutated TP53. 9 / 9
|
9
reach
"Specifically, suberoylanilide hydroxamic acid (SAHA, also known as vorinostat), a FDA approved HDACi that inhibits class I, II, and IV HDACs, induces degradation of mutant p53 by inhibiting HDAC6 activity, an essential positive regulator of Hsp90, and subsequent disruption of the HDAC6/Hsp90/mutant p53 complex, leading to mutant p53 ubiquitination by MDM2 and CHIP."